House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Liver: Perioperative Risk Assessment and Management in Patients With Cirrhosis

ACG · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

ACG perioperative cirrhosis guidance combines liver severity, portal hypertension, non-hepatic comorbidity and the planned procedure when weighing surgical benefit against harm. Cirrhosis-specific prediction supports shared decisions but does not replace clinical judgement. This summary selects preoperative assessment, modifiable risks and important procedure-specific choices; it distinguishes graded recommendations from expert key concepts.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Estimate the risk of the actual operation

  • Assess liver-related factors, extrahepatic comorbidities and surgery-specific factors together. Combine a validated cirrhosis-specific surgical risk calculator with judgement and individual circumstances rather than using a liver-severity score alone as surgical clearance. [1]
  • VOCAL-Penn incorporates operation type, while the older Mayo surgical score can overestimate risk. Because these models were developed in patients who actually underwent surgery, use them as adjuncts to joint surgical/hepatology assessment and shared decisions, not in isolation. [1]
  • Pay particular attention to ascites, encephalopathy, variceal bleeding and other manifestations of clinically significant portal hypertension, which are strongly associated with adverse postoperative outcomes. Independently assess non-hepatic illness and frailty, malnutrition and sarcopenia. [1]
  • For compensated cirrhosis when clinically significant portal hypertension is uncertain, ACG conditionally suggests liver stiffness and platelet assessment using recommended thresholds, plus cross-sectional imaging for collaterals or portal-hypertensive complications. Evidence quality is very low. [1]
  • In known liver disease with an unknown fibrosis stage, FIB-4 and/or elastography may help identify advanced fibrosis or cirrhosis when that finding would alter surgical planning. There is no need for preoperative fibrosis testing if a new compensated-cirrhosis diagnosis would not change plans or counselling. [1]
  • For selected elective-surgery patients, consider liver-transplant evaluation before surgery when projected postoperative mortality exceeds 15% at 90 days. This proposed threshold prompts consideration and contingency planning; it does not itself establish transplant eligibility or mandate listing. [1]

Address reversible risks before elective surgery

  • When feasible, treat reversible hepatic insults such as active alcohol use, viral hepatitis or autoimmune hepatitis before elective surgery. Discuss risk reduction with surgery, anaesthesia and hepatology, balancing the benefit against unacceptable delay and the risk of foregoing the operation. [1]
  • Encourage strict alcohol and tobacco cessation before elective surgery; this may reduce liver-related events, infection and wound complications. Set the cessation period by balancing surgical urgency against the benefit of abstinence over time. [1]
  • Ideally start nutritional optimisation at least 2 weeks before surgery. Target 30–35 kcal/kg/day and 1.25–1.5 g protein/kg/day using ideal body weight, with dietetic help or nasoenteric feeding when intake is insufficient. Do not restrict protein because of hepatic encephalopathy. [1]
  • For cirrhosis-related frailty or sarcopenia, consider prehabilitation before elective surgery. Improving functional capacity may reduce complications, but the supporting perioperative evidence in cirrhosis remains limited. [1]

Avoid treating laboratory abnormalities in isolation

  • Traditional INR/PT, aPTT and platelet counts do not capture the rebalanced pro- and anticoagulant effects of cirrhosis. INR is not independently associated with procedural bleeding, and giving vitamin K or blood products solely to correct it before major surgery has not shown reduced bleeding risk. [1]
  • If available, consider viscoelastic testing such as TEG to guide perioperative haemostatic management rather than relying only on conventional markers. If unavailable, the guideline considers correction of severe thrombocytopenia below 50 K/mm³ reasonable before major surgery. [1]
  • For cirrhosis with severe thrombocytopenia before an invasive procedure, ACG recommends thrombopoietin-receptor agonists dosed according to baseline platelet count to reduce transfusions and potentially bleeding; this is strong, moderate-quality guidance. Drug selection and dosing require specific assessment, including thrombotic risk, rather than assuming a class-wide interchangeable regimen. [1]

Optimise decompensation and coordinate specialist care

  • For cirrhosis with clinically significant portal hypertension and another indication for TIPS, such as refractory ascites, ACG conditionally suggests preoperative TIPS; evidence is very low quality. Decide case by case at an experienced centre with multidisciplinary review of competing benefits and contraindications, rather than routine TIPS for surgical risk alone. [1]
  • Before elective surgery, keep routine cirrhosis care current: ascites and encephalopathy control, HCC screening, variceal assessment/bleeding prophylaxis and SBP prophylaxis when indicated. Sample ascites to exclude SBP; active SBP should delay elective surgery until appropriate antibiotics are completed. [1]
  • Drain large-volume ascites before surgery and manage it postoperatively; when more than 5 L is removed, give albumin 6–8 g/L. Continue prescribed diuretics perioperatively only in the absence of acute kidney injury or major electrolyte disturbance. [1]
  • Continue lactulose and/or rifaximin for hepatic encephalopathy perioperatively, attending to sodium and drugs that worsen encephalopathy. Continue an established nonselective beta blocker for portal hypertension or secondary variceal-bleed prevention when systolic blood pressure is above 90 mmHg. [1]
  • For major hepatic surgery, ACG conditionally suggests referral to a high-volume liver surgery/transplant centre when feasible, with very-low-quality evidence. Expert key concepts also support considering such referral for elective major non-hepatic surgery in cirrhosis. [1]

Match the operation to liver status and alternatives

  • For abdominal hernia in cirrhosis, seek surgical assessment for elective repair after ascites optimisation rather than automatically deferring until an emergency. Thinning skin or ascites leakage needs close observation and consideration of emergency repair to avoid rupture. [1]
  • For an indication requiring cholecystectomy, laparoscopic surgery is generally favoured in Child–Turcotte–Pugh classes A/B. Most class C patients have prohibitive risk; in acute cholecystitis with prohibitive surgical risk, start antibiotics and consider alternative drainage if medical treatment fails. Asymptomatic gallstones do not need treatment. [1]
  • Bariatric surgery can be considered in selected well-compensated cirrhosis, with laparoscopic sleeve gastrectomy preferred. In transplant candidates with bariatric indications, sleeve gastrectomy before or during transplantation may be considered according to centre expertise; post-transplant evidence is limited. [1]

Limitations and use

  • This is selected perioperative guidance, not automatic clearance, a complete operation-specific risk estimate or a transplant-listing decision. Several key concepts rest on expert judgement, and many graded recommendations have low certainty.
  • Thrombopoietin-agonist eligibility and dosing, SBP prophylaxis criteria, detailed transfusion algorithms and cardiac surgery choices are not fully specified here. Verify the relevant specialist protocol and units before prescribing or transfusing.
  • Risk estimates and access to TIPS, viscoelastic testing, transplant evaluation and high-volume surgery must be interpreted for the individual patient and local Indian services.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Liver: Perioperative Risk Assessment and Management in Patients With Cirrhosis

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Estimate the risk of the actual operation
  • Address reversible risks before elective surgery
  • Avoid treating laboratory abnormalities in isolation
  • Optimise decompensation and coordinate specialist care
  • Match the operation to liver status and alternatives
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House